A Director at Alexion Pharmaceuticals (NASDAQ: ALXN) is Buying Shares

Today, a Director at Alexion Pharmaceuticals (NASDAQ: ALXN), Christopher J. Coughlin, bought shares of ALXN for $1.21M.

This recent transaction increases Christopher J. Coughlin’s holding in the company by 61.23% to a total of $3.12 million. Following Christopher J. Coughlin’s last ALXN Buy transaction on June 16, 2017, the stock climbed by 4.6%.

See today’s analyst top recommended stocks >>

Based on Alexion Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $944 million and quarterly net profit of $249 million. In comparison, last year the company earned revenue of $850 million and had a net profit of $170 million. The company has a one-year high of $149.34 and a one-year low of $96.18. ALXN’s market cap is $26.39B and the company has a P/E ratio of 49.24.

28 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 17 analyst ratings, the analyst consensus is Strong Buy with an average price target of $159.25, reflecting a -28.3% downside. Starting in April 2018, ALXN received 12 Buy ratings in a row.

The insider sentiment on Alexion Pharmaceuticals has been negative according to 58 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts